Search

Your search keyword '"Yared, Jean A."' showing total 496 results
Start Over Author "Yared, Jean A." Search Limiters Full Text
496 results on '"Yared, Jean A."'

1. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.

Author

Khera, Nandita, Ailawadhi, Sikander, Brazauskas, Ruta, Patel, Jinalben, Jacobs, Benjamin, Ustun, Celalettin, Ballen, Karen, Abid, Muhammad, Diaz Perez, Miguel, Al-Homsi, A, Hashem, Hasan, Hong, Sanghee, Munker, Reinhold, Schears, Raquel, Lazarus, Hillard, Ciurea, Stefan, Badawy, Sherif, Savani, Bipin, Wirk, Baldeep, LeMaistre, C, Bhatt, Neel, Beitinjaneh, Amer, Aljurf, Mahmoud, Sharma, Akshay, Cerny, Jan, Knight, Jennifer, Kelkar, Amar, Yared, Jean, Kindwall-Keller, Tamila, Winestone, Lena, Steinberg, Amir, Arnold, Staci, Seo, Sachiko, Preussler, Jaime, Hossain, Nasheed, Fingrut, Warren, Agrawal, Vaibhav, Hashmi, Shahrukh, Lehmann, Leslie, Wood, William, Rangarajan, Hemalatha, Saber, Wael, and Hahn, Theresa

Subjects
Humans, Hematopoietic Stem Cell Transplantation, Male, Female, Adult, Middle Aged, Ethnic and Racial Minorities, Adolescent, Child, Aged, Young Adult, Child, Preschool
Abstract

There has been an increase in volume as well as an improvement in overall survival (OS) after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if these changes have affected racial/ethnic minorities equally. In this observational study from the Center for International Blood and Marrow Transplant Research of 79 904 autologous (auto) and 65 662 allogeneic (allo) HCTs, we examined the volume and rates of change of autoHCT and alloHCT over time and trends in OS in 4 racial/ethnic groups: non-Hispanic Whites (NHWs), non-Hispanic African Americans (NHAAs), and Hispanics across 5 2-year cohorts from 2009 to 2018. Rates of change were compared using Poisson model. Adjusted and unadjusted Cox proportional hazards models examined trends in mortality in the 4 racial/ethnic groups over 5 study time periods. The rates of increase in volume were significantly higher for Hispanics and NHAAs vs NHW for both autoHCT and alloHCT. Adjusted overall mortality after autoHCT was comparable across all racial/ethnic groups. NHAA adults (hazard ratio [HR] 1.13; 95% confidence interval [CI] 1.04-1.22; P = .004) and pediatric patients (HR 1.62; 95% CI 1.3-2.03; P < .001) had a higher risk of mortality after alloHCT than NHWs. Improvement in OS over time was seen in all 4 groups after both autoHCT and alloHCT. Our study shows the rate of change for the use of autoHCT and alloHCT is higher in NHAAs and Hispanics than in NHWs. Survival after autoHCT and alloHCT improved over time; however, NHAAs have worse OS after alloHCT, which has persisted. Continued efforts are needed to mitigate disparities for patients requiring alloHCT.

Published
2024

3. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.

Author

Saliba, Rima, Alousi, Amin, Pidala, Joseph, Arora, Mukta, Spellman, Stephen, Hemmer, Michael, Wang, Tao, Abboud, Camille, Ahmed, Sairah, Antin, Joseph, Beitinjaneh, Amer, Buchbinder, David, Byrne, Michael, Cahn, Jean-Yves, Choe, Hannah, Hanna, Rabi, Hematti, Peiman, Kamble, Rammurti, Kitko, Carrie, Laughlin, Mary, Lekakis, Lazaros, MacMillan, Margaret, Martino, Rodrigo, Mehta, Parinda, Nishihori, Taiga, Patel, Sagar, Perales, Miguel-Angel, Rangarajan, Hemalatha, Ringdén, Olov, Rosenthal, Joseph, Savani, Bipin, Schultz, Kirk, Seo, Sachiko, Teshima, Takanori, van der Poel, Marjolein, Verdonck, Leo, Weisdorf, Daniel, Wirk, Baldeep, Yared, Jean, Schriber, Jeffrey, Champlin, Richard, and Ciurea, Stefan

Subjects
Graft-versus-host disease, Non-relapse mortality, Post-transplantation cyclophosphamide, Prophylaxis, Antilymphocyte Serum, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Male, Retrospective Studies
Abstract

Post-transplantation cyclophosphamide (PTCy) has been shown to effectively control graft-versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective registry study, we compared GvHD organ distribution, severity, and outcomes in patients with GvHD occurring after Haplo transplantation with PTCy GvHD prophylaxis (Haplo/PTCy) versus HLA-matched unrelated donor transplantation with conventional prophylaxis (MUD/conventional). We evaluated 2 cohorts: patients with grade 2 to 4 acute GvHD (aGvHD) including 264 and 1163 recipients of Haplo and MUD transplants; and patients with any chronic GvHD (cGvHD) including 206 and 1018 recipients of Haplo and MUD transplants, respectively. In comparison with MUD/conventional transplantation ± antithymocyte globulin (ATG), grade 3-4 aGvHD (28% versus 39%, P = .001), stage 3-4 lower gastrointestinal (GI) tract aGvHD (14% versus 21%, P = .01), and chronic GI GvHD (21% versus 31%, P = .006) were less common after Haplo/PTCy transplantation. In patients with grade 2-4 aGvHD, cGvHD rate after Haplo/PTCY was also lower (hazard ratio [HR] = .4, P < .001) in comparison with MUD/conventional transplantation without ATG in the nonmyeloablative conditioning setting. Irrespective of the use of ATG, non-relapse mortality rate was lower (HR = .6, P = .01) after Haplo/PTCy transplantation, except for transplants that were from a female donor into a male recipient. In patients with cGvHD, irrespective of ATG use, Haplo/PTCy transplantation had lower non-relapse mortality rates (HR = .6, P = .04). Mortality rate was higher (HR = 1.6, P = .03) during, but not after (HR = .9, P = .6) the first 6 months after cGvHD diagnosis. Our results suggest that PTCy-based GvHD prophylaxis mitigates the development of GI GvHD and may translate into lower GvHD-related non-relapse mortality rate.

Published
2022

5. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author

Wieduwilt, Matthew J, Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David I, Al-Homsi, A Samar, Muffly, Lori, Chao, Nelson J, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M, Cairo, Mitchell S, Mussetti, Alberto, Gore, Steven D, Bhatt, Vijaya Raj, Patel, Sagar S, Michelis, Fotios V, Inamoto, Yoshihiro, Badawy, Sherif M, Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard M, Ganguly, Siddhartha, Bredeson, Christopher N, Perez, Miguel Angel Diaz, Cassaday, Ryan, Savani, Bipin N, Ballen, Karen Kuhn, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S, Yared, Jean A, Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K, Solh, Melhem, Seftel, Matthew, van der Poel, Marjolein WM, Grunwald, Michael Richard, Liesveld, Jane L, Kamble, Rammurti T, McGuirk, Joseph P, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O, Krem, Maxwell, Winestone, Lena E, Gergis, Usama, Nathan, Sunita, Olsson, Richard F, Verdonck, Leo F, Sharma, Akshay, Ringden, Olle, Friend, Brian D, Cerny, Jan, Choe, Hannah K, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C, de Lima, Marcos, Litzow, Mark R, Kebriaei, Partow, Hourigan, Christopher S, Abid, Muhammad Bilal, Weisdorf, Daniel J, and Saber, Wael

Subjects
Rare Diseases, Cancer, Pediatric, Pediatric Cancer, Stem Cell Research - Nonembryonic - Human, Orphan Drug, Hematology, Stem Cell Research, Transplantation, Good Health and Well Being, Fetal Blood, Hematopoietic Stem Cell Transplantation, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Siblings, Unrelated Donors
Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Published
2022

6. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Author

Jimenez Jimenez, Antonio M, De Lima, Marcos, Komanduri, Krishna V, Wang, Trent P, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Alkhateeb, Hassan, Assal, Amer, Bacher, Ulrike, Baron, Frédéric, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Copelan, Edward, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Elsawy, Mahmoud, Gale, Robert Peter, George, Biju, Grunwald, Michael R, Hildebrandt, Gerhard C, Hogan, William J, Kanakry, Christopher G, Kansagra, Ankit, Kharfan-Dabaja, Mohamed A, Khera, Nandita, Krem, Maxwell M, Lazaryan, Aleksandr, Maakaron, Joseph, Martino, Rodrigo, McGuirk, Joseph, Michelis, Fotios V, Milone, Giuseppe, Mishra, Asmita, Murthy, Hemant S, Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F, Palmisiano, Neil, Patel, Sagar, Saad, Ayman, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Verdonck, Leo F, Wirk, Baldeep, Yared, Jean A, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S, Saber, Wael, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Genetics, Transplantation, Pediatric Research Initiative, Childhood Leukemia, Stem Cell Research, Cancer, Clinical Research, Pediatric Cancer, Rare Diseases, Pediatric, Stem Cell Research - Nonembryonic - Human, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Retrospective Studies, Risk Assessment, Transplantation Conditioning, Transplantation, Homologous, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p

Published
2021

7. Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation

Author

Mulroney, Carolyn M, Abid, Muhammad Bilal, Bashey, Asad, Chemaly, Roy F, Ciurea, Stefan O, Chen, Min, Dandoy, Christopher E, Perez, Miguel A Diaz, Friend, Brian D, Fuchs, Ephraim, Ganguly, Siddhartha, Goldsmith, Scott R, Kanakry, Christopher G, Kim, Soyoung, Komanduri, Krishna V, Krem, Maxwell M, Lazarus, Hillard M, Ljungman, Per, Maziarz, Richard, Nishihori, Taiga, Patel, Sagar S, Perales, Miguel‐Angel, Romee, Rizwan, Singh, Anurag K, Wingard, John Reid, Yared, Jean, Riches, Marcie, and Taplitz, Randy

Subjects
Prevention, Transplantation, Lung, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Hematology, Rare Diseases, Organ Transplantation, Orphan Drug, Cancer, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Community-Acquired Infections, Cyclophosphamide, Female, Graft vs Host Disease, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Kaplan-Meier Estimate, Leukemia, Living Donors, Male, Middle Aged, Myelodysplastic Syndromes, Proportional Hazards Models, Respiratory Tract Infections, Retrospective Studies, Siblings, Transplantation, Haploidentical, Virus Diseases, Young Adult, Respiratory viral infection, Post Transplant Cyclophosphamide, Allogeneic transplant, Cardiorespiratory Medicine and Haematology, Immunology
Abstract

Community respiratory viral infections (CRVIs) are associated with pulmonary function impairment, alloimmune lung syndromes and inferior survival in human leucocyte antigen (HLA)-matched allogeneic haematopoietic stem cell transplant (HCT) recipients. Although the incidence of viral infections in HLA-haploidentical HCT recipients who receive post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is reportedly increased, there are insufficient data describing the incidence of CRVIs and the impact of donor source and PTCy on transplant outcomes. Analysing patients receiving their first HCT between 2012 and 2017 for acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes, we describe comparative outcomes between matched sibling transplants receiving either calcineurin-based GVHD prophylaxis (SibCNI, N = 1605) or PTCy (SibCy, N = 403), and related haploidentical transplants receiving PTCy (HaploCy, N = 757). The incidence of CRVIs was higher for patients receiving PTCy, regardless of donor type. Patients in the HaploCy cohort who developed a CRVI by day +180 had both a higher risk of treatment-related mortality [hazard ratio (HR) 2⋅14, 99% confidence interval (CI) 1⋅13-4⋅07; P = 0⋅002] and inferior 2-year overall survival (HR 1⋅65, 99% CI 1⋅11-2⋅43; P = 0⋅001) compared to SibCNI with no CRVI. This finding justifies further research into long-term antiviral immune recovery, as well as development of preventive and treatment strategies to improve long-term outcomes in such patients.

Published
2021

9. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States

Author

Hong, Sanghee, Brazauskas, Ruta, Hebert, Kyle M, Ganguly, Siddhartha, Abdel‐Azim, Hisham, Diaz, Miguel Angel, Beattie, Sara, Ciurea, Stefan O, Szwajcer, David, Badawy, Sherif M, Gratwohl, Alois A, LeMaistre, Charles, Aljurf, Mahmoud DSM, Olsson, Richard F, Bhatt, Neel S, Farhadfar, Nosha, Yared, Jean A, Yoshimi, Ayami, Seo, Sachiko, Gergis, Usama, Beitinjaneh, Amer M, Sharma, Akshay, Lazarus, Hillard, Law, Jason, Ulrickson, Matthew, Hashem, Hasan, Schoemans, Hélène, Cerny, Jan, Rizzieri, David, Savani, Bipin N, Kamble, Rammurti T, Shaw, Bronwen E, Khera, Nandita, Wood, William A, Hashmi, Shahrukh, Hahn, Theresa, Lee, Stephanie J, Rizzo, J Douglas, Majhail, Navneet S, and Saber, Wael

Subjects
Hematology, Cancer, Clinical Research, Prevention, Transplantation, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Community Health Planning, Female, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Public Health, Risk Factors, Transplantation, Homologous, Treatment Outcome, United States, Young Adult, allogeneic transplant, community health, hematopoietic cell transplantation, survival, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThe association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.MethodsThis study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.ResultsThe median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.ConclusionsPatients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.

Published
2021

10. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Author

Tamari, Roni, McLornan, Donal P., Ahn, Kwang Woo, Estrada-Merly, Noel, Hernández-Boluda, Juan Carlos, Giralt, Sergio, Palmer, Jeanne, Gale, Robert Peter, DeFilipp, Zachariah, Marks, David I., van der Poel, Marjolein, Verdonck, Leo F., Battiwalla, Minoo, Diaz, Miguel Angel, Gupta, Vikas, Ali, Haris, Litzow, Mark Robert, Lazarus, Hillard M., Gergis, Usama, Bashey, Asad, Liesveld, Jane, Hashmi, Shahrukh, Pu, Jeffrey J., Beitinjaneh, Amer, Bredeson, Christopher, Rizzieri, David, Savani, Bipin N., Abid, Muhammad Bilal, Ganguly, Siddhartha, Agrawal, Vaibhav, Ulrike Bacher, Vera, Wirk, Baldeep, Jain, Tania, Cutler, Corey, Aljurf, Mahmoud, Kindwall-Keller, Tamila, Kharfan-Dabaja, Mohamed A., Hildebrandt, Gerhard C., Pawarode, Attaphol, Solh, Melhem M., Yared, Jean A., Grunwald, Michael R., Nathan, Sunita, Nishihori, Taiga, Seo, Sachiko, Scott, Bart L., Nakamura, Ryotaro, Oran, Betul, Czerw, Tomasz, Yakoub-Agha, Ibrahim, and Saber, Wael

Published
2023
Full Text
View/download PDF

11. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.

Author

Bejanyan, Nelli, Zhang, Meijie, Bo-Subait, Khalid, Brunstein, Claudio, Wang, Hailin, Warlick, Erica, Giralt, Sergio, Nishihori, Taiga, Martino, Rodrigo, Passweg, Jakob, Dias, Ajoy, Copelan, Edward, Hale, Gregory, Gale, Robert, Solh, Melhem, Kharfan-Dabaja, Mohamed, Diaz, Miguel, Ganguly, Siddhartha, Gore, Steven, Verdonck, Leo, Hossain, Nasheed, Kekre, Natasha, Savani, Bipin, Byrne, Michael, Kanakry, Christopher, Cairo, Mitchell, Ciurea, Stefan, Schouten, Harry, Bredeson, Christopher, Munker, Reinhold, Lazarus, Hillard, Cahn, Jean-Yves, van Der Poel, Marjolein, Rizzieri, David, Yared, Jean, Freytes, Cesar, Cerny, Jan, Aljurf, Mahmoud, Palmisiano, Neil, Pawarode, Attaphol, Bacher, Vera, Grunwald, Michael, Nathan, Sunita, Wirk, Baldeep, Hildebrandt, Gerhard, Seo, Sachiko, Olsson, Richard, George, Biju, de Lima, Marcos, Hourigan, Christopher, Sandmaier, Brenda, Litzow, Mark, Kebriaei, Partow, Saber, Wael, and Weisdorf, Daniel

Subjects
AML, DRI, MDS, Myeloablative, RIC, Adult, Aged, Disease-Free Survival, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Middle Aged, Myelodysplastic Syndromes, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous
Abstract

Compared with reduced-intensity conditioning (RIC), myeloablative conditioning (MAC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, disease-specific risk factors in AML/MDS can further inform when MAC and RIC may yield differential outcomes. We analyzed HCT outcomes stratified by the Disease Risk Index (DRI) in 4387 adults (age 40 to 65 years) to identify the impact of conditioning intensity. In the low/intermediate-risk DRI cohort, RIC was associated with lower nonrelapse mortality (NRM) (hazard ratio [HR], .74; 95% confidence interval [CI], .62 to .88; P < .001) but significantly greater relapse risk (HR, 1.54; 95% CI, 1.35 to 1.76; P < .001) and thus inferior disease-free survival (DFS) (HR, 1.19; 95% CI, 1.07 to 1.33; P = .001). In the high/very high-risk DRI cohort, RIC was associated with marginally lower NRM (HR, .83; 95% CI, .68 to 1.00; P = .051) and significantly higher relapse risk (HR, 1.23; 95% CI, 1.08 to 1.41; P = .002), leading to similar DFS using either RIC or MAC. These data support MAC over RIC as the preferred conditioning intensity for patients with AML/MDS with low/intermediate-risk DRI, but with a similar benefit as RIC in high/very high-risk DRI. Novel MAC regimens with less toxicity could benefit all patients, but more potent antineoplastic approaches are needed for the high/very-high risk DRI group.

Published
2021

12. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

Author

Im, Annie, Rashidi, Armin, Wang, Tao, Hemmer, Michael, MacMillan, Margaret, Pidala, Joseph, Jagasia, Madan, Pavletic, Steven, Majhail, Navneet, Weisdorf, Daniel, Abdel-Azim, Hisham, Agrawal, Vaibhav, Al-Homsi, A, Aljurf, Mahmoud, Askar, Medhat, Auletta, Jeffery, Bashey, Asad, Beitinjaneh, Amer, Bhatt, Vijaya, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Choe, Hannah, Ciurea, Stefan, Daly, Andrew, Perez, Miguel, Farhadfar, Nosha, Gadalla, Shahinaz, Gale, Robert, Ganguly, Siddhartha, Gergis, Usama, Hanna, Rabi, Hematti, Peiman, Herzig, Roger, Hildebrandt, Gerhard, Lad, Deepesh, Lee, Catherine, Lehmann, Leslie, Lekakis, Lazaros, Kamble, Rammurti, Kharfan-Dabaja, Mohamed, Khandelwal, Pooja, Martino, Rodrigo, Murthy, Hemant, Nishihori, Taiga, OBrien, Tracey, Olsson, Richard, Patel, Sagar, Perales, Miguel-Angel, Prestidge, Tim, Qayed, Muna, Romee, Rizwan, Schoemans, Hélène, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Strair, Roger, Teshima, Takanori, Urbano-Ispizua, Alvaro, Van der Poel, Marjolein, Vij, Ravi, Wagner, John, William, Basem, Wirk, Baldeep, Yared, Jean, Spellman, Steve, Arora, Mukta, and Hamilton, Betty

Subjects
Adult, Cyclophosphamide, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Risk Factors, Transplantation Conditioning
Abstract

Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from the Center for International Blood and Marrow Transplant Research on adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloid leukemia who underwent PTCy-based haplo-HCT (2013 to 2016) were analyzed and categorized into 4 groups based on myeloablative (MA) or reduced-intensity conditioning (RIC) and bone marrow (BM) or peripheral blood (PB) graft source. In total, 646 patients were identified (MA-BM = 79, MA-PB = 183, RIC-BM = 192, RIC-PB = 192). The incidence of grade 2 to 4 acute GVHD at 6 months was highest in MA-PB (44%), followed by RIC-PB (36%), MA-BM (36%), and RIC-BM (30%) (P = .002). The incidence of chronic GVHD at 1 year was 40%, 34%, 24%, and 20%, respectively (P < .001). In multivariable analysis, there was no impact of stem cell source or conditioning regimen on grade 2 to 4 acute GVHD; however, older donor age (30 to 49 versus

Published
2020

13. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research.

Author

Buchbinder, David, Brazauskas, Ruta, Bo-Subait, Khalid, Ballen, Karen, Parsons, Susan, John, Tami, Hahn, Theresa, Sharma, Akshay, Steinberg, Amir, DSouza, Anita, Kumar, Anita, Yoshimi, Ayami, Wirk, Baldeep, Shaw, Bronwen, Freytes, César, LeMaistre, Charles, Bredeson, Christopher, Dandoy, Christopher, Almaguer, David, Marks, David, Szwajcer, David, Hale, Gregory, Schouten, Harry, Hashem, Hasan, Schoemans, Hélène, Murthy, Hemant, Lazarus, Hillard, Cerny, Jan, Tay, Jason, Yared, Jean, Adekola, Kehinde, Schultz, Kirk, Lehmann, Leslie, Burns, Linda, Aljurf, Mahmoud, Diaz, Miguel, Majhail, Navneet, Farhadfar, Nosha, Kamble, Rammurti, Olsson, Richard, Schears, Raquel, Seo, Sachiko, Beattie, Sara, Chhabra, Saurabh, Savani, Bipin, Badawy, Sherif, Ganguly, Siddhartha, Ciurea, Stefan, Marino, Susana, Gergis, Usama, Kuwatsuka, Yachiyo, Inamoto, Yoshihiro, Khera, Nandita, Hashmi, Shahrukh, Wood, William, and Saber, Wael

Subjects
Bone marrow transplantation, Lost to follow-up, Stem cell transplantation, Survivor, Adult, Aged, Child, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Survivors, Transplantation Conditioning, Transplantation, Homologous
Abstract

Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.

Published
2020

14. Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study

Author

Papanicolaou, Genovefa A, Ustun, Celalettin, Young, Jo-Anne H, Chen, Min, Kim, Soyoung, Ahn, Kwang Woo, Komanduri, Krishna, Lindemans, Caroline, Auletta, Jeffery J, Riches, Marcie L, Abdel-Azim, Hisham, Ahmed, Ibrahim A, Aljurf, Mahmoud, Antin, Joseph, Ballen, Karen Kuhn, Beitinjaneh, Amer, Brown, Valerie I, Cerny, Jan, Champlin, Richard, Chao, Nelson, Chhabra, Saurabh, Dahi, Parastoo B, Daly, Andrew, Dandoy, Christopher, Dvorak, Christopher C, Forman, Stephen, Ganguly, Siddhartha, Hashmi, Shahrukh K, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard, Ljungman, Per, Malone, Adriana K, Murthy, Nishihori, Taiga, Page, Kristin, Pingali, Ravi, Reddy, Vijay, Saad, Ayman, Savani, Bipin N, Seftel, Matthew, Szer, Jeffrey, Vij, Ravi, Weisdorf, Daniel, William, Basem M, Williams, Kirsten, Wirk, Baldeep, and Yared, Jean

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Cancer, Vaccine Related, Transplantation, Rare Diseases, Hematology, Emerging Infectious Diseases, Clinical Research, Good Health and Well Being, Adolescent, Adult, Aged, Anti-Bacterial Agents, Bacteremia, Child, Child, Preschool, Gram-Positive Bacterial Infections, Hematopoietic Stem Cell Transplantation, Humans, Infant, Leukemia, Myeloid, Acute, Middle Aged, Myelodysplastic Syndromes, Retrospective Studies, Transplantation Conditioning, Vancomycin, Vancomycin-Resistant Enterococci, Young Adult, vancomycin-resistant Enterococcus, bacteremia, hematopoietic stem cell transplantation, mortality, CIBMTR® Infection and Immune Reconstitution Working Committee, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundWe examined the impact of vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI) on outcomes of allogeneic hematopoietic cell transplantation (HCT) utilizing the Center for International Blood and Marrow Transplant Research database.MethodsAdult and pediatric patients (N = 7128) who underwent first HCT for acute leukemia or myelodysplastic syndrome from 2008 through 2012 were analyzed as 3 groups-VRE BSI, non-VRE BSI, without BSI-according to BSI status at 100 days (D100) after allogeneic HCT. Multivariable models examined the effect of VRE BSI for overall survival (OS) and nonrelapse mortality (NRM) at 1 year.ResultsOf 7128 patients, 258 (3.2%) had VRE BSI, 2398 (33.6%) had non-VRE BSI, and 4472 (63%) had no BSI. The median time to VRE BSI and non-VRE BSI were D11 and D15, respectively. Compared with non-VRE BSI patients, VRE BSI patients were older, had advanced-stage acute leukemia, and received umbilical cord blood (UCB) allografts. In multivariable models, VRE BSI was associated with lower OS (relative risk [RR], 2.9;(99% confidence interval [CI], 2.2-3.7) and increased NRM (RR, 4.7; 99% CI, 3.6-6.2) (P < .0001) for both. Other predictors for worse OS and increased NRM were non-VRE BSI, older age, advanced disease stage, UCB allograft, - mismatch, comorbidity index ≥3, and cytomegalovirus seropositivity (P < .001 for all variables).ConclusionsVRE BSI is associated with lowest OS and highest NRM compared with patients without BSI or non-VRE BSI. Novel interventions that address the pathophysiology of VRE BSI have the potential of improving survival after HCT.

Published
2019

15. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.

Author

Bejanyan, Nelli, Kim, Soyoung, Hebert, Kyle M, Kekre, Natasha, Abdel-Azim, Hisham, Ahmed, Ibrahim, Aljurf, Mahmoud, Badawy, Sherif M, Beitinjaneh, Amer, Boelens, Jaap Jan, Diaz, Miguel Angel, Dvorak, Christopher C, Gadalla, Shahinaz, Gajewski, James, Gale, Robert Peter, Ganguly, Siddhartha, Gennery, Andrew R, George, Biju, Gergis, Usama, Gómez-Almaguer, David, Vicent, Marta Gonzalez, Hashem, Hasan, Kamble, Rammurti T, Kasow, Kimberly A, Lazarus, Hillard M, Mathews, Vikram, Orchard, Paul J, Pulsipher, Michael, Ringden, Olle, Schultz, Kirk, Teira, Pierre, Woolfrey, Ann E, Saldaña, Blachy Dávila, Savani, Bipin, Winiarski, Jacek, Yared, Jean, Weisdorf, Daniel J, Antin, Joseph H, and Eapen, Mary

Subjects
Transplantation, Regenerative Medicine, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Prevention, Hematology, Rare Diseases, Good Health and Well Being, Adolescent, Adult, Anemia, Aplastic, Bone Marrow Transplantation, Clinical Decision-Making, Disease Management, Graft vs Host Disease, HLA Antigens, Histocompatibility Testing, Humans, Prognosis, Severity of Illness Index, Siblings, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Young Adult
Abstract

Allogeneic bone marrow transplantation (BMT) is curative therapy for the treatment of patients with severe aplastic anemia (SAA). However, several conditioning regimens can be used for BMT. We evaluated transplant conditioning regimens for BMT in SAA after HLA-matched sibling and unrelated donor BMT. For recipients of HLA-matched sibling donor transplantation (n = 955), fludarabine (Flu)/cyclophosphamide (Cy)/antithymocyte globulin (ATG) or Cy/ATG led to the best survival. The 5-year probabilities of survival with Flu/Cy/ATG, Cy/ATG, Cy ± Flu, and busulfan/Cy were 91%, 91%, 80%, and 84%, respectively (P = .001). For recipients of 8/8 and 7/8 HLA allele-matched unrelated donor transplantation (n = 409), there were no differences in survival between regimens. The 5-year probabilities of survival with Cy/ATG/total body irradiation 200 cGy, Flu/Cy/ATG/total body irradiation 200 cGy, Flu/Cy/ATG, and Cy/ATG were 77%, 80%, 75%, and 72%, respectively (P = .61). Rabbit-derived ATG compared with equine-derived ATG was associated with a lower risk of grade II to IV acute graft-versus-host disease (GVHD) (hazard ratio [HR], 0.39; P < .001) but not chronic GVHD. Independent of conditioning regimen, survival was lower in patients aged >30 years after HLA-matched sibling (HR, 2.74; P < .001) or unrelated donor (HR, 1.98; P = .001) transplantation. These data support Flu/Cy/ATG and Cy/ATG as optimal regimens for HLA-matched sibling BMT. Although survival after an unrelated donor BMT did not differ between regimens, use of rabbit-derived ATG may be preferred because of lower risks of acute GVHD.

Published
2019

16. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1

Author

Ustun, Celalettin, Kim, Soyoung, Chen, Min, Beitinjaneh, Amer M, Brown, Valerie I, Dahi, Parastoo B, Daly, Andrew, Diaz, Miguel Angel, Freytes, Cesar O, Ganguly, Siddhartha, Hashmi, Shahrukh, Hildebrandt, Gerhard C, Lazarus, Hillard M, Nishihori, Taiga, Olsson, Richard F, Page, Kristin M, Papanicolaou, Genovefa, Saad, Ayman, Seo, Sachiko, William, Basem M, Wingard, John R, Wirk, Baldeep, Yared, Jean A, Perales, Miguel-Angel, Auletta, Jeffery J, Komanduri, Krishna V, Lindemans, Caroline A, and Riches, Marcie L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Stem Cell Research - Nonembryonic - Human, Hematology, Infectious Diseases, Transplantation, Stem Cell Research, Clinical Research, Infection, Good Health and Well Being, Adult, Bacterial Infections, Hematopoietic Stem Cell Transplantation, Humans, Infections, Leukemia, Myeloid, Acute, Myeloablative Agonists, Remission Induction, Time Factors, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Cardiovascular medicine and haematology
Abstract

Presumably, reduced-intensity/nonmyeloablative conditioning (RIC/NMA) for allogeneic hematopoietic cell transplantation (alloHCT) results in reduced infections compared with myeloablative conditioning (MAC) regimens; however, published evidence is limited. In this Center for International Blood and Marrow Transplant Research study, 1755 patients (aged ≥40 years) with acute myeloid leukemia in first complete remission were evaluated for infections occurring within 100 days after T-cell replete alloHCT. Patients receiving RIC/NMA (n = 777) compared with those receiving MAC (n = 978) were older and underwent transplantation more recently; however, the groups were similar regarding Karnofsky performance score, HCT-comorbidity index, and cytogenetic risk. One or more infections occurred in 1045 (59.5%) patients (MAC, 595 [61%]; RIC/NMA, 450 [58%]; P = .21) by day 100. The median time to initial infection after MAC conditioning occurred earlier (MAC, 15 days [range,

Published
2019

17. Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study

Author

Abidi, Maheen Z, Hari, Parameswaran, Chen, Min, Kim, Soyoung, Battiwala, Minoo, Dahi, Parastoo Bahrami, Diaz, Miguel Angel, Gale, Robert Peter, Ganguly, Siddhartha, Gergis, Usama, Green, Jaime, Hildebrandt, Gerhard, Hill, Joshua A, Komanduri, Krishna, Lazarus, Hillard, Marks, David, Nishihori, Taiga, Olsson, Richard, Seo, Sachiko, Ustun, Celalettin, Yared, Jean, Yin, Dwight, Wingard, John, Wirk, Baldeep Mona, Auletta, Jeffrey, Lindemans, Caroline, and Riches, Marcie

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Stem Cell Research, HIV/AIDS, Regenerative Medicine, Stem Cell Research - Nonembryonic - Human, Cancer, Infectious Diseases, Transplantation, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Child, Child, Preschool, DNA, Viral, Female, Hematopoietic Stem Cell Transplantation, Humans, Longitudinal Studies, Male, Middle Aged, Transplantation Conditioning, Virus Diseases, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Limited data exist on characteristics of central nervous system viruses (CNS-V) in allogeneic hematopoietic stem cell transplant (HCT) recipients. Between 2007 and 2015, the Center for International Blood and Marrow Transplant Research (CIBMTR) received information on 27,532 patients undergoing HCT. Of these, centers reported 165 HCT recipients with CNS-V detected in cerebrospinal fluid within 6 months after HCT. CNS viruses predominantly included human herpes virus 6 (HHV-6) (73%), followed by Epstein-Barr Virus (10%), cytomegalovirus (3%), varicella zoster virus (3%), herpes simplex virus (3%) and Adenovirus (3%). Median time of viral detection in CNS was 31 days after HCT; and viral detection was earlier in patients with CNS HHV-6. Concurrent viremia occurred in 52% of patients. Cord blood transplant recipients (CBT) accounted for the majority (53%) of patients with CNS-V. Myeloablative conditioning (65%), use of fludarabine (63%), or use of anti-thymocyte globulin (61%) were also predominant. Overall survival from the time of detection of CNS-V was 50% at 6 months and 30% at 5 years. Infections were the leading cause of death (32%). In summary, CBT recipients predominated in the population with CNS-V. Outcomes after CNS-V were poor with significant mortality seen in the first 6 months.

Published
2019

18. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation

Author

Brunstein, Claudio G, Pasquini, Marcelo C, Kim, Soyoung, Fei, Mingwei, Adekola, Kehinde, Ahmed, Ibrahim, Aljurf, Mahmoud, Agrawal, Vaibhav, Auletta, Jeffrey J, Battiwalla, Minoo, Bejanyan, Nelli, Bubalo, Joseph, Cerny, Jan, Chee, Lynette, Ciurea, Stefan O, Freytes, Cesar, Gadalla, Shahinaz M, Gale, Robert Peter, Ganguly, Siddhartha, Hashmi, Shahrukh K, Hematti, Peiman, Hildebrandt, Gerhard, Holmberg, Leona A, Lahoud, Oscar B, Landau, Heather, Lazarus, Hillard M, de Lima, Marcos, Mathews, Vikram, Maziarz, Richard, Nishihori, Taiga, Norkin, Maxim, Olsson, Richard, Reshef, Ran, Rotz, Seth, Savani, Bipin, Schouten, Harry C, Seo, Sachiko, Wirk, Baldeep M, Yared, Jean, Mineishi, Shin, Rogosheske, John, and Perales, Miguel-Angel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Rare Diseases, Transplantation, Lymphoma, Clinical Research, Cancer, Obesity, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Aged, Antineoplastic Agents, Drug Dosage Calculations, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Mortality, Multiple Myeloma, Recurrence, Transplantation Conditioning, Transplantation, Autologous, Autologous hematopoietic cell transplantation, Conditioning regimen, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index (BMI) ≥ 30 kg/m2. Dose adjustment was defined as a reduction in standard dosing ≥20%, based on ideal, reported dosing and actual weights. We included 2 groups of US patients who had received autoHCT between 2008 and 2014. Specifically, we included patients with multiple myeloma (MM, n = 1696) treated with high-dose melphalan and patients with Hodgkin or non-Hodgkin lymphomas (n = 781) who received carmustine, etoposide, cytarabine, and melphalan conditioning. Chemotherapy dose was adjusted in 1324 patients (78%) with MM and 608 patients (78%) with lymphoma. Age, sex, BMI, race, performance score, comorbidity index, and disease features (stage at diagnosis, disease status, and time to transplant) were similar between dose groups. In multivariate analyses for MM, adjusting for melphalan dose and for center effect had no impact on overall survival (P = .894) and treatment-related mortality (TRM) (P = .62), progression (P = .12), and progression-free survival (PFS; P = .178). In multivariate analyses for lymphoma, adjusting chemotherapy doses did not affect survival (P = .176), TRM (P = .802), relapse (P = .633), or PFS (P = .812). No center effect was observed in lymphoma. This study demonstrates that adjusting chemotherapy dose before autoHCT in obese patients with MM and lymphoma does not influence mortality. These results do not support adjusting chemotherapy dose in this population.

Published
2019

19. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Author

Shadman, Mazyar, Pasquini, Marcelo, Ahn, Kwang Woo, Chen, Yue, Turtle, Cameron J., Hematti, Peiman, Cohen, Jonathon B., Khimani, Farhad, Ganguly, Siddhartha, Merryman, Reid W., Yared, Jean A., Locke, Frederick L., Ahmed, Nausheen, Munshi, Pashna N., Beitinjaneh, Amer, Reagan, Patrick M., Herrera, Alex F., Sauter, Craig S., Kharfan-Dabaja, Mohamed A., and Hamadani, Mehdi

Published
2022
Full Text
View/download PDF

20. A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products

Author

Atanackovic, Djordje, primary, Iraguha, Thierry, additional, Omili, Destiny, additional, Avila, Stephanie V., additional, Fan, Xiaoxuan, additional, Kocoglu, Mehmet, additional, Gebru, Etse, additional, Baker, Jillian M., additional, Dishanthan, Nishanthini, additional, Dietze, Kenneth A., additional, Oluwafemi, Ayooluwakiitan, additional, Hardy, Nancy M., additional, Yared, Jean A., additional, Hankey, Kim, additional, Dahiya, Saurabh, additional, Rapoport, Aaron P., additional, and Luetkens, Tim, additional

Published
2024
Full Text
View/download PDF

22. RGI-2001 with CNI-Based Prophylaxis Demonstrates Better Acute Gvhd-Free Survival Following Myeloablative Allohct without Increased Relapse: Comparison of a Multi-Center Phase 2b Study with a Contemporaneous CIBMTR Cohort

Author

Chen, Dr. Yi-Bin, primary, Farhan, Shatha, additional, Lekakis, Lazaros J., additional, Schiller, Gary J., additional, Yared, Jean A., additional, Mapara, Markus Y., additional, Assal, Amer, additional, Choe, Hannah, additional, DeFilipp, Zachariah, additional, Lee, Dana D, additional, Lane, Hayley, additional, Burns, Linda J., additional, Zhang, Mei-Jie, additional, Bye, Matthew, additional, Gooley, Ted A., additional, and Saad, Ayman, additional

Published
2024
Full Text
View/download PDF

23. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Author

Farhadfar, Nosha, Dias, Ajoy, Wang, Tao, Fretham, Caitrin, Chhabra, Saurabh, Murthy, Hemant S., Broglie, Larisa, D'Souza, Anita, Gadalla, Shahinaz M., Gale, Robert Peter, Hashmi, Shahrukh, Al-Homsi, A. Samer, Hildebrandt, Gerhard C., Hematti, Peiman, Rizzieri, David, Chee, Lynette, Lazarus, Hillard M., Bredeson, Christopher, Jaimes, Edgar A., Beitinjaneh, Amer, Bashey, Asad, Prestidge, Tim, Krem, Maxwell M., Marks, David I., Benoit, Stefanie, Yared, Jean A., Nishihori, Taiga, Olsson, Richard F., Freytes, Cesar O., Stadtmauer, Edward, Savani, Bipin N., Sorror, Mohamed L., Ganguly, Siddhartha, Wingard, John R., and Pasquini, Marcelo

Published
2021
Full Text
View/download PDF

24. Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis

Author

Hamadani, Mehdi, Kanate, Abraham S, DiGilio, Alyssa, Ahn, Kwang Woo, Smith, Sonali M, Lee, Jong Wook, Ayala, Ernesto, Chao, Nelson, Hari, Parameswaran, Bolaños-Meade, Javier, Gress, Ronald, Anderson, Niels Smedegaard, Chen, Yi-Bin, Farooq, Umar, Schiller, Gary, Yared, Jean, Sureda, Anna, Fenske, Timothy S, and Olteanu, Horatiu

Subjects
Cancer, Rare Diseases, Stem Cell Research, Stem Cell Research - Nonembryonic - Human, Transplantation, Hematology, Clinical Research, Good Health and Well Being, Adolescent, Adult, Aged, Databases, Factual, Disease Progression, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Large Granular Lymphocytic, Male, Middle Aged, Recurrence, Remission Induction, Survival Analysis, Transplantation, Homologous, Young Adult, Aggressive natural killer cell leukemia, Myeloablative, Allogeneic transplantation, Reduced-intensity conditioning, Clinical Sciences, Immunology
Abstract

Aggressive NK cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis, with a median survival of only 2 months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in patients with ANKL. Twenty-one patients with a centrally confirmed diagnosis of ANKL were included. Median patient age was 42 years and 15 patients (71%) were Caucasian. Fourteen patients (67%) were in complete remission (CR) at the time of alloHCT, and 5 patients had active disease. Median follow-up of survivors was 25 months (range, 12 to 116). The 2-year estimates of nonrelapse mortality, relapse/progression, progression-free (PFS), and overall survival (OS) were 21%, 59%, 20%, and 24%, respectively. The 2-year PFS of patients in CR at the time of alloHCT was significantly better than that of patients with active disease at transplantation (30% versus 0%; P = .001). The 2-year OS in similar order was 38% versus 0% (P

Published
2017

25. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Author

Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, null, null, Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, and null, null

Abstract

Purpose: Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. Methods: Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. Results: Three hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P = .0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P = .0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P = .575). Conclusion: Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Published
2024

26. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Author

Nazha, Aziz, Hu, Zhen-Huan, Wang, Tao, Lindsley, R. Coleman, Abdel-Azim, Hisham, Aljurf, Mahmoud, Bacher, Ulrike, Bashey, Asad, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, DeFilipp, Zachariah, Diaz, Miguel Angel, Farhadfar, Nosha, Gadalla, Shahinaz M., Gale, Robert Peter, George, Biju, Gergis, Usama, Grunwald, Michael R., Hamilton, Betty, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Kalaycio, Matt, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Majhail, Navneet S., Murthy, Hemant S., Nathan, Sunita, Nishihori, Taiga, Pawarode, Attaphol, Rizzieri, David, Sabloff, Mitchell, Savani, Bipin N., Schachter, Levanto, Schouten, Harry C., Seo, Sachiko, Shah, Nirav N., Solh, Melhem, Valcárcel, David, Vij, Ravi, Warlick, Erica, Wirk, Baldeep, Wood, William A., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald M., Scott, Bart L., Nakamura, Ryotaro, and Saber, Wael

Published
2020
Full Text
View/download PDF

27. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS

Author

Gupta, Vikas, Kim, Soyoung, Hu, Zhen-Huan, Liu, Ying, Aljurf, Mahmoud, Bacher, Ulrike, Beitinjaneh, Amer, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, Gadalla, Shahinaz M., Gale, Robert Peter, Ganguly, Siddhartha, George, Biju, Gerds, Aaron T., Gergis, Usama, Hamilton, Betty K., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Kamble, Rammurti T., Kindwall-Keller, Tamila, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark, Maziarz, Richard T., Nishihori, Taiga, Olsson, Richard F., Rizzieri, David, Savani, Bipin N., Seo, Sachiko, Solh, Melhem, Szer, Jeff, Verdonck, Leo F., Wirk, Baldeep, Woolfrey, Ann, Yared, Jean A., Alyea, Edwin P., Popat, Uday R., Sobecks, Ronald M., Scott, Bart L., Nakamura, Ryotaro, and Saber, Wael

Published
2020
Full Text
View/download PDF

29. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Author

Zhou, Zheng, Nath, Rajneesh, Cerny, Jan, Wang, Hai-Lin, Zhang, Mei-Jie, Abdel-Azim, Hisham, Agrawal, Vaibhav, Ahmed, Gulrayz, Al-Homsi, A. Samer, Aljurf, Mahmoud, Alkhateeb, Hassan B., Assal, Amer, Bacher, Ulrike, Bajel, Ashish, Bashir, Qaiser, Battiwalla, Minocher, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Choe, Hannah, Copelan, Edward, Cutler, Corey, Damlaj, Moussab B., DeFilipp, Zachariah, De Lima, Marcos, Diaz, Miguel Angel, Farhadfar, Nosha, Foran, James, Freytes, César O., Gerds, Aaron T., Gergis, Usama, Grunwald, Michael R., Gul, Zartash, Hamadani, Mehdi, Hashmi, Shahrukh, Hertzberg, Mark, Hildebrandt, Gerhard C., Hossain, Nasheed, Inamoto, Yoshihiro, Isola, Luis, Jain, Tania, Kamble, Rammurti T., Khan, Muhammad Waqas, Kharfan-Dabaja, Mohamed A., Kebriaei, Partow, Kekre, Natasha, Khera, Nandita, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark, Liu, Hongtao, Marks, David I., Martino, Rodrigo, Mathews, Vikram, Mishra, Asmita, Murthy, Hemant S., Nagler, Arnon, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Palmisiano, Neil, Patel, Sagar S., Patnaik, Mrinal M., Pawarode, Attaphol, Perales, Miguel-Angel, Politikos, Ioannis, Popat, Uday, Rizzieri, David, Sandmaier, Brenda M., Savani, Bipin N., Seo, Sachiko, Shah, Nirav N., Uy, Geoffrey L., Valcárcel, David, Verdonck, Leo F., Waller, Edmund K., Wang, Youjin, Weisdorf, Daniel, Wirk, Baldeep, Wong, Eric, Yared, Jean A., and Saber, Wael

Published
2020
Full Text
View/download PDF

30. Survival following allogeneic transplant in patients with myelofibrosis

Author

Gowin, Krisstina, Ballen, Karen, Ahn, Kwang Woo, Hu, Zhen-Huan, Ali, Haris, Arcasoy, Murat O., Devlin, Rebecca, Coakley, Maria, Gerds, Aaron T., Green, Michael, Gupta, Vikas, Hobbs, Gabriela, Jain, Tania, Kandarpa, Malathi, Komrokji, Rami, Kuykendall, Andrew T., Luber, Kierstin, Masarova, Lucia, Michaelis, Laura C., Patches, Sarah, Pariser, Ashley C., Rampal, Raajit, Stein, Brady, Talpaz, Moshe, Verstovsek, Srdan, Wadleigh, Martha, Agrawal, Vaibhav, Aljurf, Mahmoud, Angel Diaz, Miguel, Avalos, Belinda R., Bacher, Ulrike, Bashey, Asad, Beitinjaneh, Amer M., Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey S., DeFilipp, Zachariah, Gadalla, Shahinaz M., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh K., Kharfan-Dabaja, Mohamed A., Kindwall-Keller, Tamila, Kröger, Nicolaus, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Rowe, Jacob M., Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Tamari, Roni, Verdonck, Leo F., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Nakamura, Ryotaro, Mesa, Ruben, and Saber, Wael

Published
2020
Full Text
View/download PDF

31. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

Author

DeFilipp, Zachariah, Ancheta, Richard, Liu, Ying, Hu, Zhen-Huan, Gale, Robert Peter, Snyder, David, Schouten, Harry C., Kalaycio, Matt, Hildebrandt, Gerhard C., Ustun, Celalettin, Daly, Andrew, Ganguly, Siddhartha, Inamoto, Yoshihiro, Litzow, Mark, Szer, Jeffrey, Savoie, Mary Lynn, Hossain, Nasheed, Kharfan-Dabaja, Mohamed A., Hamadani, Mehdi, Reshef, Ran, Bajel, Ashish, Schultz, Kirk R., Gadalla, Shahinaz, Gerds, Aaron, Liesveld, Jane, Juckett, Mark B., Kamble, Rammurti, Hashmi, Shahrukh, Abdel-Azim, Hisham, Solh, Melhem, Bacher, Ulrike, Lazarus, Hillard, Olsson, Richard, Cahn, Jean-Yves, Grunwald, Michael R., Savani, Bipin N., Yared, Jean, Rowe, Jacob M., Cerny, Jan, Chaudhri, Naeem A., Aljurf, Mahmoud, Beitinjaneh, Amer, Seo, Sachiko, Nishihori, Taiga, Hsu, Jack W., Ramanathan, Muthalagu, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, and Saber, Wael

Published
2020
Full Text
View/download PDF

32. Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation

Author

Sabloff, Mitchell, Chhabra, Saurabh, Wang, Tao, Fretham, Caitrin, Kekre, Natasha, Abraham, Allistair, Adekola, Kehinde, Auletta, Jeffery J., Barker, Christopher, Beitinjaneh, Amer M., Bredeson, Christopher, Cahn, Jean-Yves, Diaz, Miguel Angel, Freytes, Cesar, Gale, Robert Peter, Ganguly, Siddhartha, Gergis, Usama, Guinan, Eva, Hamilton, Betty K., Hashmi, Shahrukh, Hematti, Peiman, Hildebrandt, Gerhard, Holmberg, Leona, Hong, Sanghee, Lazarus, Hillard M., Martino, Rodrigo, Muffly, Lori, Nishihori, Taiga, Perales, Miguel-Angel, Yared, Jean, Mineishi, Shin, Stadtmauer, Edward A., Pasquini, Marcelo C., and Loren, Alison W.

Published
2019
Full Text
View/download PDF

33. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases

Author

Broglie, Larisa, Friend, Brian D., Chhabra, Saurabh, Logan, Brent R., Bupp, Caitrin, Schiller, Gary, Savani, Bipin N., Stadtmauer, Edward, Abraham, Allistair A., Aljurf, Mahmoud, Badawy, Sherif M., Perez, Miguel Angel Diaz, Guinan, Eva C., Hashem, Hasan, Krem, Maxwell M., Lazarus, Hillard M., Rotz, Seth J., Wirk, Baldeep, Yared, Jean A., Pasquini, Marcelo, Thakar, Monica S., and Sorror, Mohamed L.

Published
2023
Full Text
View/download PDF

34. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma

Author

Ahmed, Sairah, Kanakry, Jennifer A., Ahn, Kwang W., Litovich, Carlos, Abdel-Azim, Hisham, Aljurf, Mahmoud, Bacher, Vera Ulrike, Bejanyan, Nelli, Cohen, Jonathon B., Farooq, Umar, Fuchs, Ephraim J., Bolaños-Meade, Javier, Ghosh, Nilanjan, Herrera, Alex F., Hossain, Nasheed M., Inwards, David, Kanate, Abraham S., Martino, Rodrigo, Munshi, Pashna N., Murthy, Hemant, Mussetti, Alberto, Nieto, Yago, Perales, Miguel-Angel, Romee, Rizwan, Savani, Bipin N., Seo, Sachiko, Wirk, Baldeep, Yared, Jean A., Sureda, Ana, Fenske, Timothy S., and Hamadani, Mehdi

Published
2019
Full Text
View/download PDF

35. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation

Author

Saad, Ayman, Lamb, Lawrence, Wang, Tao, Hemmer, Michael T., Spellman, Stephen, Couriel, Daniel, Alousi, Amin, Pidala, Joseph, Abdel-Azim, Hisham, Agrawal, Vaibhav, Aljurf, Mahmoud, Beitinjaneh, Amer M., Bhatt, Vijaya Raj, Buchbinder, David, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Chhabra, Saurabh, Diaz, Miguel Angel, Farhan, Shatha, Floisand, Yngvar, Frangoul, Hadar A., Gadalla, Shahinaz M., Gajewski, James, Gale, Robert Peter, Gandhi, Manish, Gergis, Usama, Hamilton, Betty Ky, Hematti, Peiman, Hildebrandt, Gerhard C., Kamble, Rammurti T., Kanate, Abraham S., Khandelwal, Pooja, Lazaryan, Aleksandr, MacMillan, Margaret, Marks, David I., Martino, Rodrigo, Mehta, Parinda A., Nishihori, Taiga, Olsson, Richard F., Patel, Sagar S., Qayed, Muna, Rangarajan, Hemalatha G., Reshef, Ran, Ringden, Olle, Savani, Bipin N., Schouten, Harry C., Schultz, Kirk R., Seo, Sachiko, Shaffer, Brian C., Solh, Melhem, Teshima, Takanori, Urbano-Ispizua, Alvaro, Verdonck, Leo F., Vij, Ravi, Waller, Edmund K., William, Basem, Wirk, Baldeep, Yared, Jean A., Yu, Lolie C., Arora, Mukta, and Hashmi, Shahrukh

Published
2019
Full Text
View/download PDF

36. The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time

Author

Prokopishyn, Nicole L., Logan, Brent R., Kiefer, Deidre M., Sees, Jennifer A., Chitphakdithai, Pintip, Ahmed, Ibrahim A., Anderlini, Paolo N., Beitinjaneh, Amer M., Bredeson, Christopher, Cerny, Jan, Chhabra, Saurabh, Daly, Andrew, Diaz, Miguel Angel, Farhadfar, Nosha, Frangoul, Haydar A., Ganguly, Siddhartha, Gastineau, Dennis A., Gergis, Usama, Hale, Gregory A., Hematti, Peiman, Kamble, Rammurti T., Kasow, Kimberly A., Lazarus, Hillard M., Liesveld, Jane L., Murthy, Hemant S., Norkin, Maxim, Olsson, Richard F., Papari, Mona, Savani, Bipin N., Szer, Jeffrey, Waller, Edmund K., Wirk, Baldeep, Yared, Jean A., Pulsipher, Michael A., Shah, Nirali N., Switzer, Galen E., O'Donnell, Paul V., Confer, Dennis L., and Shaw, Bronwen E.

Published
2019
Full Text
View/download PDF

37. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades

Author

Kilari, Deepak, D'Souza, Anita, Fraser, Raphael, Qayed, Muna, Davila, Omar, Agrawal, Vaibhav, Diaz, Miguel Angel, Chhabra, Saurabh, Cerny, Jan, Copelan, Edward, Farhadfar, Nosha, Freytes, Cesar O., Gale, Robert Peter, Ganguly, Siddhartha, Hildebrandt, Gerhard C., Holmberg, Leona, Kamble, Rammurti T., Kapoor, Prashant, Lazarus, Hillard, Lee, Cindy, Murthy, Hemant S., Naik, Seema, Nishihori, Taiga, Saad, Ayman, Savani, Bipin N., Seo, Sachiko, Warwick, Anne, Wirk, Baldeep, Yared, Jean A., Nieto, Yago, and Hari, Parameswaran

Published
2019
Full Text
View/download PDF

38. Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation

Author

Inamoto, Yoshihiro, Petriček, Igor, Burns, Linda, Chhabra, Saurabh, DeFilipp, Zachariah, Hematti, Peiman, Rovó, Alicia, Schears, Raquel, Shah, Ami, Agrawal, Vaibhav, Ahmed, Aisha, Ahmed, Ibrahim, Ali, Asim, Aljurf, Mahmoud, Alkhateeb, Hassan, Beitinjaneh, Amer, Bhatt, Neel, Buchbinder, Dave, Byrne, Michael, Callander, Natalie, Fahnehjelm, Kristina, Farhadfar, Nosha, Gale, Robert Peter, Ganguly, Siddhartha, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Horn, Erich, Jakubowski, Ann, Kamble, Rammurti T., Law, Jason, Lee, Catherine, Nathan, Sunita, Penack, Olaf, Pingali, Ravi, Prasad, Pinki, Pulanic, Drazen, Rotz, Seth, Shreenivas, Aditya, Steinberg, Amir, Tabbara, Khalid, Tichelli, André, Wirk, Baldeep, Yared, Jean, Basak, Grzegorz W., Battiwalla, Minoo, Duarte, Rafael, Savani, Bipin N., Flowers, Mary E.D., Shaw, Bronwen E., and Valdés-Sanz, Nuria

Published
2019
Full Text
View/download PDF

39. Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells

Author

Kathari, Yamini K., primary, Ahmad, Haroon, additional, Kallen, Michael E., additional, Koka, Rima, additional, Omili, Destiny, additional, Iraguha, Thierry, additional, Clement, Jean, additional, Pham, Lily, additional, Khalid, Mazhar, additional, Fan, Xiaoxuan, additional, Gebru, Etse, additional, Lesho, Patricia, additional, Park, Esther, additional, Dishanthan, Nishanthini, additional, Baker, Jillian M., additional, Dietze, Kenneth A., additional, Hankey, Kim G., additional, Badros, Ashraf, additional, Yared, Jean A., additional, Dahiya, Saurabh, additional, Hardy, Nancy M., additional, Kocoglu, Hakan, additional, Luetkens, Tim, additional, Rapoport, Aaron P., additional, and Atanackovic, Djordje, additional

Published
2023
Full Text
View/download PDF

40. S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY

Author

Roddie, Claire, primary, Sandhu, Karamjeet, additional, Tholouli, Eleni, additional, Shaughnessy, Paul, additional, Barba Suñol, Pere, additional, Nuno Direito de Morais Guerreiro, Manuel, additional, Abedi, Mehrdad, additional, Bishop, Michael, additional, Yared, Jean, additional, Ghobadi, Armin, additional, Yallop, Deborah, additional, Logan, Aaron, additional, Amer, Beitinjaneh, additional, Pantin, Jeremy, additional, Arellano, Martha L, additional, Chaganti, Sridhar, additional, Malladi, Ram, additional, Menne, Tobias, additional, Escamilla, Virginia, additional, Hodby, Katharine, additional, Gundabolu, Krishna, additional, Mountjoy, Luke, additional, Odwyer, Kristen, additional, Abedin, Sameem, additional, Alkhateeb, Hassan, additional, Shah, Bijal, additional, Basilico, Silvia, additional, Cluxton, Deborah, additional, Dawes, Joanna, additional, Lao-Sirieix, Pierre, additional, Raymond, Meera, additional, Shang, Justin, additional, Hu, Yanqing, additional, Pittari, Gianfranco, additional, Saxena, Kapil, additional, Brugger, Wolfram, additional, Zhang, Y, additional, Pule, Martin, additional, Park, Daniel, additional, De Angelo, Daniel, additional, and Jabbour, Elias, additional

Published
2023
Full Text
View/download PDF

41. Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation

Author

Phelan, Rachel, Im, Annie, Hunter, Rebecca L., Inamoto, Yoshihiro, Lupo-Stanghellini, Maria Teresa, Rovo, Alicia, Badawy, Sherif M., Burns, Linda, Eissa, Hesham, Murthy, Hemant S., Prasad, Pinki, Sharma, Akshay, Suelzer, Elizabeth, Agrawal, Vaibhav, Aljurf, Mahmoud, Baker, Karen, Basak, Grzegorz W., Buchbinder, David, DeFilipp, Zachariah, Grkovic, Lana Desnica, Dias, Ajoy, Einsele, Hermann, Eisenberg, Michael L., Epperla, Narendranath, Farhadfar, Nosha, Flatau, Arthur, Gale, Robert Peter, Greinix, Hildegard, Hamilton, Betty K., Hashmi, Shahrukh, Hematti, Peiman, Jamani, Kareem, Maharaj, Dipnarine, Murray, John, Naik, Seema, Nathan, Sunita, Pavletic, Steven, Peric, Zinaida, Pulanic, Drazen, Ross, Richard, Salonia, Andrea, Sanchez-Ortega, Isabel, Savani, Bipin N., Schechter, Tal, Shah, Ami J., Smith, Stephanie M., Snowden, John A., Steinberg, Amir, Tremblay, Douglas, Vij, Sarah C., Walker, Lauren, Wolff, Daniel, Yared, Jean A., Schoemans, Hélène, and Tichelli, André

Published
2022
Full Text
View/download PDF

42. Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis

Author

Wood, William A., Brazauskas, Ruta, Hu, Zhen-Huan, Abdel-Azim, Hisham, Ahmed, Ibrahim A., Aljurf, Mahmoud, Badawy, Sherif, Beitinjaneh, Amer, George, Biju, Buchbinder, David, Cerny, Jan, Dedeken, Laurence, Diaz, Miguel Angel, Freytes, Cesar O., Ganguly, Siddhartha, Gergis, Usama, Almaguer, David Gomez, Gupta, Ashish, Hale, Gregory, Hashmi, Shahrukh K., Inamoto, Yoshihiro, Kamble, Rammurti T., Adekola, Kehinde, Kindwall-Keller, Tamila, Knight, Jennifer, Kumar, Lalit, Kuwatsuka, Yachiyo, Law, Jason, Lazarus, Hillard M., LeMaistre, Charles, Olsson, Richard F., Pulsipher, Michael A., Savani, Bipin N., Schultz, Kirk R., Saad, Ayman A., Seftel, Matthew, Seo, Sachiko, Shea, Thomas C., Steinberg, Amir, Sullivan, Keith, Szwajcer, David, Wirk, Baldeep, Yared, Jean, Yong, Agnes, Dalal, Jignesh, Hahn, Theresa, Khera, Nandita, Bonfim, Carmem, Atsuta, Yoshiko, and Saber, Wael

Published
2018
Full Text
View/download PDF

43. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia

Author

Hogan, William, Battiwalla, Minoo, Copelan, Edward, Hildebrandt, Gerhard, Ganguly, Sid, Majhail, Navneet, Woolfrey, Ann, Nivison-Smith, Ian, Hertzberg, Mark, Diaz, Miguel Angel, Jakubowski, Ann, Ustun, Celalettin, Yong, Agnes, Freytes, Cesar, DeFilipp, Zachariah, Inamoto, Yoshi, Cahn, Jean-Yves, Savani, Bipin, Yared, Jean, Bajel, Ashish, Bacher, Ulrike, Uy, Geoffrey, Rizzieri, David, Wieduwilt, Matthew, Schultz, Kirk, Grunwald, Michael, Kamble, Rammurti, Qayed, Muna, Brammer, Jonathan, Ballen, Karen, Khera, Nandita, Schouten, Harry, Bierings, Marc, Kanakry, Christopher, Wood, William Allen, Saad, Ayman, Savoie, Lynn, Hamilton, Betty Ky, Aljurf, Mahmoud, Vij, Ravi, Pawarode, Attaphol, Olsson, Richard, Wirk, B. Mona, Beitinjaneh, Amer, Seo, Sachiko, Cerny, Jan, Akpek, Gorgun, Norkin, Maxim, Nishihori, Taiga, Lazaryan, Aleksandr, Sabloff, Mitchell, Kebriaei, Partow, Anasetti, Claudio, Zhang, Mei-Jie, Wang, Hai-Lin, Aldoss, Ibrahim, de Lima, Marcos, Khoury, H. Jean, Sandmaier, Brenda M., Horowitz, Mary M., Artz, Andrew, Bejanyan, Nelli, Ciurea, Stefan, Lazarus, Hillard M., Gale, Robert Peter, Litzow, Mark, Bredeson, Christopher, Seftel, Matthew D., Pulsipher, Michael A., Boelens, Jaap-Jan, Alvarnas, Joseph, Champlin, Richard, Forman, Stephen, Pullarkat, Vinod, Weisdorf, Daniel, and Marks, David I.

Published
2018
Full Text
View/download PDF

44. Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less

Author

Stroncek, David F., Shaw, Bronwen E., Logan, Brent R., Kiefer, Deidre M., Savani, Bipin N., Anderlini, Paolo, Bredeson, Christopher N., Hematti, Peiman, Ganguly, Siddhartha, Diaz, Miguel Angel, Abdel-Azim, Hisham, Ahmed, Ibrahim, Maharaj, Dipnarine, Seftel, Matthew, Beitinjaneh, Amer, Seo, Sachiko, Yared, Jean A., Halter, Joerg, O'Donnell, Paul V., Hale, Gregory A., DeFilipp, Zachariah, Lazarus, Hillard, Liesveld, Jane L., Zhou, Zheng, Munshi, Pashna, Olsson, Richard F., Kasow, Kimberly Anne, Szer, Jeffrey, Switzer, Galen E., Chitphakdithai, Pintip, Shah, Nirali, Confer, Dennis L., and Pulsipher, Michael A.

Published
2018
Full Text
View/download PDF

45. Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)

Author

Kline, Kathryn, primary, Chen, Wengen, additional, Kallen, Michael E., additional, Koka, Rima, additional, Omili, Destiny, additional, Fan, Xiaoxuan, additional, Iraguha, Thierry, additional, Gebru, Etse, additional, Dishanthan, Nishanthini, additional, Baker, Jillian M., additional, Dietze, Kenneth A., additional, Yared, Jean A., additional, Hankey, Kim, additional, Dahiya, Saurabh, additional, Niederhaus, Silke V., additional, Dunleavy, Kieron, additional, Hardy, Nancy M., additional, Luetkens, Tim, additional, Rapoport, Aaron P., additional, and Atanackovic, Djordje, additional

Published
2023
Full Text
View/download PDF

46. Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy

Author

Orfali, Nina, Zhang, Mei-Jie, Allbee-Johnson, Mariam, Boelens, Jaap Jan, Artz, Andrew S., Brunstein, Claudio G., McNiece, Ian K., Milano, Filippo, Abid, Muhammad Bilal, Chee, Lynette, Diaz, Miguel A., Grunwald, Michael R., Hematti, Peiman, Hsu, Jingmei, Lazarus, Hillard M., Munshi, Pashna N., Prestidge, Timothy, Ringden, Olle, Rizzieri, David, Riches, Marcie L., Seo, Sachiko, Solh, Melhem, Solomon, Scott, Szwajcer, David, Yared, Jean, van Besien, Koen, and Eapen, Mary

Published
2021
Full Text
View/download PDF

47. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults

Author

Metheny, Leland, Callander, Natalie S., Hall, Aric C., Zhang, Mei-Jei, Bo-Subait, Khalid, Wang, Hai-Lin, Agrawal, Vaibhav, Al-Homsi, A. Samer, Assal, Amer, Bacher, Ulrike, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Bredeson, Chris, Byrne, Michael, Cairo, Mitchell, Cerny, Jan, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Freytes, César O., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Kanakry, Christopher G., Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Lee, Jong Wook, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Ringdén, Olov, Rizzieri, David, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Yared, Jean A., Hourigan, Christopher S., Kebriaei, Partow, Litzow, Mark, Sandmaier, Brenda M., Saber, Wael, Weisdorf, Daniel, and de Lima, Marcos

Published
2021
Full Text
View/download PDF

48. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

Author

Oran, Betül, Ahn, Kwang Woo, Fretham, Caitrin, Beitinjaneh, Amer, Bashey, Asad, Pawarode, Attaphol, Wirk, Baldeep, Scott, Bart L., Savani, Bipin N., Bredeson, Christopher, Weisdorf, Daniel, Marks, David I., Rizzieri, David, Copelan, Edward, Hildebrandt, Gerhard C., Hale, Gregory A., Murthy, Hemant S., Lazarus, Hillard M., Cerny, Jan, Liesveld, Jane L., Yared, Jean A., Yves-Cahn, Jean, Szer, Jeffrey, Verdonck, Leo F., Aljurf, Mahmoud, van der Poel, Marjolein, Litzow, Mark, Kalaycio, Matt, Grunwald, Michael R., Diaz, Miguel Angel, Sabloff, Mitchell, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Farhadfar, Nosha, Reshef, Ran, Olsson, Richard F., Gale, Robert Peter, Nakamura, Ryotaro, Seo, Sachiko, Chhabra, Saurabh, Hashmi, Shahrukh, Farhan, Shatha, Ganguly, Siddhartha, Nathan, Sunita, Nishihori, Taiga, Jain, Tania, Agrawal, Vaibhav, Bacher, Ulrike, Popat, Uday, and Saber, Wael

Published
2021
Full Text
View/download PDF

49. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma

Author

Cornell, Robert F., D'Souza, Anita, Kassim, Adetola A., Costa, Luciano J., Innis-Shelton, Racquel D., Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I., Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M., Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Published
2017
Full Text
View/download PDF

50. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma

Author

Cornell, Robert F., Bachanova, Veronika, D'Souza, Anita, Woo-Ahn, Kwang, Martens, Michael, Huang, Jiaxing, Al-Homsi, A. Samer, Chhabra, Saurabh, Copelan, Edward, Diaz, Miguel-Angel, Freytes, Cesar O., Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hildebrandt, Gerhard, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Lazarus, Hillard M., Marks, David I., Nishihori, Taiga, Olsson, Richard F., Saad, Ayman, Usmani, Saad, Vesole, David H., Yared, Jean, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results